Eswatini vs Rwanda: Average cost of multi drug-resistant tuberculosis treatment
Eswatini
840 constant 2022 US$
in 2024
Rwanda
876 constant 2022 US$
in 2024
Eswatini rank
59th
Rwanda rank
56th
Average cost of multi drug-resistant tuberculosis treatment over time
- Eswatini
- Rwanda
How they compare
Rwanda currently reports 876 constant 2022 US$ against 840 constant 2022 US$ in Eswatini, a difference of 36 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Eswatini ahead.
Eswatini ranks 59th and Rwanda ranks 56th of 92 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,118 constant 2022 US$ | 1,084 constant 2022 US$ | 5,034 constant 2022 US$ | Eswatini |
| 2020s | 2,824 constant 2022 US$ | 958.6 constant 2022 US$ | 1,865 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eswatini or Rwanda?
- Rwanda, at 876 constant 2022 US$ against 840 constant 2022 US$ in Eswatini as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eswatini and Rwanda?
- 36 constant 2022 US$, with Rwanda ahead.
- How many years of comparable data are there for Eswatini and Rwanda?
- 8 years are reported by both, from 2017 to 2024.
- How do Eswatini and Rwanda rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eswatini ranks 59th and Rwanda ranks 56th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.